The role of globalization in drug development and access to orphan drugs: Orphan drug legislation in the US/EU and in Latin America

F1000Research

Volumn 4, Issue , 2015, Pages

  Arnold, Renée J G ^a,b,c   Bighash, Lida ^d   Bryón Nieto, Alejandro ^e   Tannus Branco de Araújo, Gabriela ^f   Gay Molina, Juan Gabriel ^f   Augustovski, Federico ^g  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Arnold Consultancy and Technology   (United States)

^c Quorum Consulting Inc   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e HEORT   (Colombia)

^f AxiaBio Life Sciences ^*  (Mexico)

^g INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ARGENTINA; ARTICLE; BRAZIL; CHILE; COLOMBIA; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG DESIGN; DRUG LEGISLATION; EUROPE; GEOGRAPHIC DISTRIBUTION; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SERVICE; MEDICAL SOCIETY; MEXICO; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; PERU; REIMBURSEMENT; SOUTH AND CENTRAL AMERICA; STRATEGIC PLANNING; UNITED STATES;

EID: 84928138558     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.4268.1     Document Type: Article

References (25)

1. http://www.orpha.net/consor/cgi-bin/index.php[Accessed August 1, 2013].
2. Denis A Mergaert L Fostier C: Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy. 2010;8(5):343-50. 20804226 10.2165/11536990-000000000-00000
3. www.eurordis.org[Accessed August 1, 2013].
4. Sharma A Jacob A Tandon M: Orphan drug: Development trends and strategies. J Pharm Bioallied Sci. 2010;2(4):290-9. 21180460 10.4103/0975-7406.72128 2996062
5. Interfarma. Rare Diseases: Contributions for a National Policy.2013. Reference Source
6. http://www.icord.se[Accessed August 4, 2013].
7. Forman J Taruscio D Llera VA: The need for worldwide policy and action plans for rare diseases. Acta paediatr. 2012;101(8):805-7. 22519914 10.1111/j.1651-2227.2012.02705.x 3443385
8. http://orphandruganaut.wordpress.com/2013/01/30/orphan-drugs-in-mexico/[Accessed August 2, 2013].
9. Wong-Rieger D: State of the art of rare disease activities around the world: overview of the non-European landscape. 6th European Conference on Rare Diseases and Orphan Products. Brussels, Belgium: Orphanet J Rare Dis. 2012;7(Suppl 2):A2. 3504552
10. http://www.checkorphan.org/grid/news/people/argentina-and-peru-making-progress-with-new-rare-disease-laws-legislated-in-both-countries[Accessed August 2, 2013].
11. Ronconi LM: The right to health: a model for determining the contents of the minimum core and the periphery. Salud colect. 2012;8(2):131-49. 23995542 10.1590/S1851-82652012000200003
12. Ley 1392 de 2010.2010. Reference Source
13. Ley 1438 de 2011.2011. Reference Source
14. Colombia avanza en la identificación de los pacientes con enfermedades huérfanas.2014. Reference Source
15. Re: Public Consultation N°7 of April 10, 2013.2013.
16. Nice Citizens Council Report: Ultra Orphan Drugs.2004. Reference Source
17. Urbinati D Masetti L Toumi M: Early Access Programmes (EAPS): review of European system.2012. Reference Source
18. Drummond M Towse A: Orphan drugs policies: a suitable case for treatment. Eur J Health Econ. 2014;15(4):335-40. 24435513 10.1007/s10198-014-0560-1
19. Sistema de tutelaje de de tecnologias sanitarias emergentes. Superintendencia de servicios de salud. Resolución N 2206/2013. Reference Source
20. Reveiz L Chapman E Torres R: Right-to-health litigation in three Latin American countries: a systematic literature review. Rev Panam Salud Publica. 2013;33(3):213-22. 23698141 10.1590/S1020-49892013000300008
21. Brazil. Ministry of Health. Ordinance No. 199, 30 of January of 2014. Reference Source
22. Brazil. MoH. Secretary of Science, Technology and Strategic Inputs. Public consultation No. 20, 26 of September of 2014. Reference Source
23. Brazil. MoH. Secretary of Science, Technology and Strategic Inputs. Department of Management and Merger of Health Technology. Prioritization Protocols and Therapeutic Guidelines for Integrated Management of People with Rare Diseases.2014. Reference Source
24. Medicamentos Huérfanos. COFEPRIS: Comisión Federal para la protección contra Riesgos Sanitarios.2011 and 2013. Reference Source
25. Comunicados de Prensa No. 142/2014. México D.F. 17 September 2014. Reference Source